GRB2 and myeloid sarcoma: Further, the intronic variant rs9900529 in GRB2 was one of the 200 non-MHC loci identified in the to date largest multi-centric study of MS genetic risk from the IMSGC [2] and it has been identified as associated with the response to interferon-beta in MS [47].